GNPX Earnings — Genprex, Inc. Common Stock Post-ER Performance | BigEarnings
GNPX — Genprex, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$0.79
Market Cap$8.3M
P/E—
52W Range$0.74 – $55.00
Next Earnings2026-08-13
About Genprex, Inc. Common Stock
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).